[go: up one dir, main page]

CN109513006A - It is a kind of to treat metabolic syndrome morbidity drug and its measuring method - Google Patents

It is a kind of to treat metabolic syndrome morbidity drug and its measuring method Download PDF

Info

Publication number
CN109513006A
CN109513006A CN201811548146.4A CN201811548146A CN109513006A CN 109513006 A CN109513006 A CN 109513006A CN 201811548146 A CN201811548146 A CN 201811548146A CN 109513006 A CN109513006 A CN 109513006A
Authority
CN
China
Prior art keywords
metabolic syndrome
phytosterol
onset
medicine
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811548146.4A
Other languages
Chinese (zh)
Inventor
王济芳
张海鸣
潘瑞蓉
尹卫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiliated Hospital of Jiangsu University
Original Assignee
Affiliated Hospital of Jiangsu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiliated Hospital of Jiangsu University filed Critical Affiliated Hospital of Jiangsu University
Priority to CN201811548146.4A priority Critical patent/CN109513006A/en
Publication of CN109513006A publication Critical patent/CN109513006A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention belongs to pharmaceutical technology field, disclose it is a kind of treat metabolic syndrome morbidity drug and its measuring method, show phytosterol and blood pressure, BMI, fasting blood-glucose, total cholesterol, triglycerides, LDL cholesterol level and hs-CRP negatively correlated (equal P < 0.01).Phytosterol and waistline and waist-to-hipratio are negatively correlated (P < 0.01), but with smoking, drink, HbA1c non-correlation.In addition, phytosterol and metabolic syndrome are positively correlated (r=0.15, P=0.03).Present invention demonstrates that phytosterol is horizontal and body mass index, waistline, total cholesterol and high-sensitive C-reactive protein are negatively correlated, but with high-density lipoprotein cholesterol, take in phytosterol and be positively correlated；It is proposed that phytosterol plays an important role during metabolic syndrome.

Description

It is a kind of to treat metabolic syndrome morbidity drug and its measuring method
Technical field
The invention belongs to pharmaceutical technology field more particularly to a kind of treat metabolic syndrome morbidity drug and its measurement side Method.
Background technique
2 times of metabolic syndrome (MetS) and All-cause death risk increase, 2 times of mortality risk increase, and 2 type glycosurias Sick risk increases by 3 times.MetS is defined as 3 kinds or more in following 5 kinds of metabolic risk factors: abdominal obesity, sweet Oily three esters increase, and high-density lipoprotein (HDL) cholesterol reduces, and blood pressure increases and/or fasting blood-glucose raising phytosterol is knot It is similar to cholesterol height on structure.Campesterol and sitosterol are two kinds of the most abundant phytosterols, they are not closed in human body At.Their plasma concentration is closely related, they are the Substitute Indexes of cholesterol absorption.It has been confirmed that the increased plant of moderate Sterol intake may also reduce the blood lipid of general population.Epidemiological study about this problem always exists dispute.One A little researchers have checked blood plasma phytosterol in the participant that Ludwigshafen risk and cardiovascular health (LURIC) are studied With the relationship of cholesterol metabolic and CAD severity.Some researchers have confirmed that phytosterol can reduce blood lipid.So And never studied the relationship between MetS and phytosterol.
In conclusion problem of the existing technology is:
Not yet explore the risk of the shortage phytosterol of reflection metabolic syndrome feature completely；Metabolic syndrome is in recent years It is increasingly taken seriously, has previously ignored the effect of phytosterol in food, so never specific data.
Summary of the invention
In view of the problems of the existing technology, metabolic syndrome morbidity drug and its measurement are treated the present invention provides a kind of Method.
The invention is realized in this way a kind of treat metabolic syndrome morbidity drug, the treatment metabolic syndrome morbidity Drug is object sterol.
It is described another object of the present invention is to provide a kind of measuring method for the treatment of metabolic syndrome morbidity drug Treat metabolic syndrome morbidity drug measuring method the following steps are included:
Step 1, progress Chi-square Test or t examine the feature with comparative studies sample in MetS state aspect；Use MetS Replicate analysis；
Step 2 calculates Pearson correlation coefficients to assess the pass between intake phytosterol and clinic and laboratory measurement Connection；The odd number ratio OR of the existing adjustment of metabolic syndrome, and the result analyzed are calculated using multiple logic regression analysis Indicate that there is 95% confidence interval CI with OR；
Step 3, statistical analysis is considered significant using SPSS19.0 editions progress value < 0.05 P.
Further, the standard of the measuring method diagnosis metabolic syndrome of the treatment metabolic syndrome morbidity drug: (1) abdomen Portion is fat, waistline: male > 90cm, women > 85cm or BMI > 30Kg/m2；(2) Serum Triglyceride increase > 1.7mmol/L or 150mg/dl；(3) LDL-C increases: male < 0.9mmol/L, < 35mg/dl, women < 1.0mmol/L, < 1.0mg/d1；(4) blood Press raising > 140/90mmHg or treatment anti-hypertension；(5) fasting blood glucose level is high；Or glucose tolerance reduces or insulin supports Anti- or diabetes；(6) ratio of urinary albumin and kreatinin: > 30mg/g or albumin excretion rate 20g/min.
Further, the T2DM or IFG of the measuring method of the treatment metabolic syndrome morbidity drug are determined by following all Justice determines: (1) fasting blood glucose level < 100mg/dl；(2) oral hypoglycemic agents or insulin therapy；(3) diabetic history is reported.
Advantages of the present invention and good effect are as follows: present invention demonstrates that phytosterol and blood pressure, BMI, fasting blood-glucose, total gallbladder are solid Alcohol, triglycerides, LDL cholesterol level and hs-CRP negatively correlated (equal P < 0.01).Phytosterol is in waistline and waist-to-hipratio Negatively correlated (P < 0.01), but with smoking, drink, HbA1c non-correlation.In addition, phytosterol is positively correlated with metabolic syndrome (r=0.15, P=0.03).Diabetic's (HbAlc > 6.5% or the patient for receiving diabetes drug treatment) (n=36) Phytosterol value is lower than nothing and suffers from patient's diabetes (n=64) (259 ± 31vs.367 ± 13, P=0.0268).In addition, plant steroid Alcohol level and body mass index, waistline, total cholesterol and high-sensitive C-reactive protein are negatively correlated, but and high-density lipoprotein cholesterol, Intake phytosterol is positively correlated；It is proposed that phytosterol plays an important role during metabolic syndrome.
Detailed description of the invention
Fig. 1 is the measuring method flow chart that the present invention implements the treatment metabolic syndrome morbidity drug provided.
Fig. 2 is that the present invention implements provide BMI (-): BMI < 24kg/m2, BMI (+): BM >=24kg/m2；HP (-): < 140/ 90mmHg, HP (+): >=140/90mmHg；DM (-): aglycosuria medical history, fasting blood-glucose < 6.1mmol/L now.DM (+) before this: Previously there is diabetic history (A)；Antidiabetic drug or insulin .TG (-):<150mg/dl is used now, TG (+):>=150mg/ dl；TC (-):<200mg/dl, TC (+):>=200mg/dl；LDL-C (-):<100mg/dl, LDL-C (+):>=100mg/dl, HDL-C (-): < 40mg/dl；HDL-C (+): >=40mg/dl；Hs-CRP (-):<0.3mg/dl, Hs-CRP (+):>=0.3mg/dl (B) schematic diagram.
Specific embodiment
In order to make the objectives, technical solutions, and advantages of the present invention clearer, with reference to embodiments, to the present invention It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to Limit the present invention.
Application principle of the invention is further described with reference to the accompanying drawing.
Treatment metabolic syndrome morbidity drug provided in an embodiment of the present invention is object sterol.
As shown in Figure 1, the measuring method for the treatment of metabolic syndrome morbidity drug provided in an embodiment of the present invention includes following Step:
S101: carrying out Chi-square Test or t is examined with comparative studies sample in terms of MetS state (be not present or exist) Feature；Then MetS replicate analysis is used；
S102: Pearson correlation coefficients are calculated to assess the pass between intake phytosterol and clinic and laboratory measurement Connection；The odd number ratio (OR) of the existing adjustment of metabolic syndrome, and the knot analyzed are calculated using multiple logic regression analysis Fruit indicates have 95% confidence interval (CI) with OR；
S103: statistical analysis is considered using SPSS19.0 editions (SPSS, Chicago, IL, USA) progress value < 0.05 .P It is significant.
The present invention provides the standard of diagnosis metabolic syndrome: (1) abdominal obesity (waistline: male > 90cm, women > 85cm) Or BMI > 30Kg/m2；(2) Serum Triglyceride increase > 1.7mmol/L or 150mg/dl；(3) LDL-C increases: male < 0.9mmol/L (< 35mg/dl), women < 1.0mmol/L (< 1.0mg/d1)；(4) blood pressure increases (> 140/90mmHg) or treats Anti-hypertension；(5) fasting blood glucose level is high；Or glucose tolerance reduces or insulin resistance or diabetes；(6) urinary albumin with The ratio of kreatinin: > 30mg/g or albumin excretion rate 20g/min；
T2DM or IFG is determined by following all definition: (1) fasting blood glucose level < 100mg/dl；(2) oral hypoglycemic agents Or insulin therapy；(3) diabetic history is reported.
Application effect of the invention is explained in detail below with reference to test.
1, method
Metabolic syndrome used to be diagnosed by the World Health Organization (WHO), because existing in following six kinds of ingredients Two or more are based on T2DM (diabetes B) or the standard of IFG (glucose tolerance reduction): (1) abdominal obesity (waistline: male Property > 90cm, women > 85cm) or BMI > 30Kg/m2；(2) Serum Triglyceride increase > 1.7mmol/L or 150mg/dl；(3) LDL-C increases: male < 0.9mmol/L (< 35mg/dl), women < 1.0mmol/L (< 1.0mg/d1)；(4) blood pressure increase (> 140/90mmHg) or treatment anti-hypertension；(5) fasting blood glucose level is high；Or glucose tolerance reduces or insulin resistance or sugar Urine disease；(6) ratio of urinary albumin and kreatinin: > 30mg/g or albumin excretion rate 20g/min.T2DM or IFG is by following institute Some definition determine: (1) fasting blood glucose level < 100mg/dl；(2) oral hypoglycemic agents or insulin therapy；(3) diabetes are reported History.Dietary Investigation is carried out using 24 hour diets of the retrospective approach to all metabolic syndrome patients, so as to even Continue three days acquisition dietary intakes.Then the mean intake of sterol in daily ration was calculated according to Chinese food component list in 2002.
2, it statisticallys analyze
Unless otherwise stated, all data are indicated with ratio, SD or ratio are indicated.Firstly, carrying out Chi-square Test Or t examines the feature with comparative studies sample in terms of MetS state (be not present or exist).Then the present invention uses MetS weight Complex analysis, because dichotomy is edvariable, (quantity is MetS standard and each ingredient of MetS to a continuous variable (waistline, triglycerides, HDL cholesterol levels, blood pressure and blood glucose etc.).Pearson correlation coefficients are calculated to assess intake plant steroid Being associated between alcohol and clinic and laboratory measurement.The existing tune of metabolic syndrome is calculated using multiple logic regression analysis Whole odd number ratio (OR), and the result analyzed is indicated with OR, is had 95% confidence interval (CI).All tests are all two-sided 's.All statistical analysis are considered significant using SPSS19.0 editions (SPSS, Chicago, IL, USA) progress value < 0.05 .P 's.
3, result
The baseline characteristic of 3.1 all subjects and correlation analysis with phytosterol
As shown in table 1, the average BMI of subject, blood glucose level, blood pressure and blood lipid level are slightly above standard value, reflect The characteristic feature of metabolic syndrome patient.It is analyzed by phytosterol data, according to BMI, hypertension, diabetes, total cholesterol (TC) it is grouped with triacylglycerol (TG) exponent pair metabolic syndrome.The present invention observes that phytosterol has accumulated all fingers Mark, such as BMI, TC, the blood pressure (table 1) of TG and metabolic syndrome.
The baseline clinical and biochemical characteristics of table 1- subject and correlation analysis with phytosterol
Phytosterol and blood pressure, BMI, fasting blood-glucose, total cholesterol, triglycerides, LDL cholesterol level and hs-CRP are in Negatively correlated (equal P < 0.01).Phytosterol and waistline and waist-to-hipratio are negatively correlated (P < 0.01), but with smoking, drink, HbA1c without Correlation.In addition, phytosterol and serum phytosterol are positively correlated (r=0.15, P=0.03).(table 1)
3.2 take in the comparison of study subject according to the phytosterol of MS
Overweight (BMI24 >=kg/m2) (n=57) subject intake phytosterol level be higher than non-BMI (BMI < 24kg/m2) (n=43) (have .374 ± 18mg, P in the subject of 423 ± 23vs hypertension (>=140/90mmHg) (n=61) =0.0025).Diabetic (glycosylated hemoglobin >=6.5% or receiving treating diabetes) (n=36), phytosterol are horizontal Lower than non-diabetic patients (n=64) (259 ± 31vs.367 ± 13mg, P=0.0268) and horizontal the height (>=150mg/ of TG Dl subject)) (n=73), it is higher than TG normal level (< 150mg/dl) (n=27) (401 ± 20vs.381 ± 22mg, P= 0.0047).In the subject of LDL cholesterol horizontal high (LDL-C) (>=100mg/dl) (n=53), phytosterol add value Lower than the people (n=47) (345 ± 18vs.396 ± 30mg, P=0.0034) of LDL-C horizontal normal (< 100mg/dL), TC is horizontal The subject of high (>=200mg/dl) is lower than subject (392 ± 22vs.405 ± 37) mg, P=0.0317 of normal level).Separately On the one hand, the phytosterol value of the subject of HDL cholesterol levels low (HDL-C) (< 40mg/dL) (n=26) is higher than HDL-C water Straight and even normal person (>=40mg/d) dl) (n=74) (411 ± 33vs.395 ± 19mg, P=0.0422).In addition, the present invention selects height Index of the sensitivity c reactive protein (hs-CRP) as assessment MS.The subject's of high hs-CRP (>=0.3mg/dl) (n=60) Phytosterol value is lower than subject (336) ± 22vs.383 ± 27mg, P=of low hs-CRP (< 0.3mg/dl) (n=40) 0.0039).(table 2, Fig. 2)
Table 2: according to the feature and phytosterol of the study subject of MS
The analysis of 3.3 multivariate logistic regressions, the presence of Negative selection metabolic syndrome
Whether the present invention has studied phytosterol independent related to the presence of metabolic syndrome.Including age, blood pressure, glycosuria Disease, BMI, WC, FBG, TG, TC, LDL-C, HDL-C, hs-CRP and phytosterol level are as independent variable.BMI (or every 1-SD (95%CI), 1.95 (1.14-2.40)；P < 0.01), waistline environment (the every 1-SD of OR (95%CI), 1.45 (1.09-2.12)；P< 0.01), TG (or every 1-SD (95%CI), 2.97 (1.73-3.33)；P < 0.01) and hs-CRP (OR=1-SD (95%CI), 3.45(1.84-4.03)；P < 0.01) it is independent related to the increase of metabolic syndrome risk.The presence of HDL-C and metabolic syndrome is in Negative correlation (the every 1-SD of OR (95%CI), 0.46 (0.27-0.80)；P<0.01).Finally, phytosterol and metabolic syndrome are deposited In negatively correlated, blood pressure unrelated with the age, diabetes, BMI, WC, HbA1c, FBG, TG, TC, LDL-C, HDL-C and hs-CRP It is independent variable.(OR1-SD (95%CI), 0.37 (0.22-0.64)；P < 0.01) (table 3).
The analysis of 3. multivariate logistic regression of table, the presence of Negative selection metabolic syndrome
Including age, blood pressure, diabetes, BMI, WC, FBG, TG, TC, LDL-C, HDL-C, hs-CRP and phytosterol water It is flat to be used as independent variable.
3.4 result
Phytosterol only enters sterol in the mammalian body by diet comprising one group.Vegetable oil, in nut and avocado There are relatively great amount of phytosterols.Research of the invention also demonstrates, BMI is the high BMI of metabolic syndrome patient, hypertension, High TG, hs-CRP, like food oil, and nut and investigation result of the invention also indicate that their phytosterol intake is higher.
Phytosterol has many important physiological functions.Effect in censored human health and disease.Meanwhile Many experiments show that, rich in phytosterol and its saturated derivatives in diet, such as stanols can inhibit the absorption of cholesterol, make Blood plasma LDL concentration reduces 10-14%.
Some researchers have confirmed that the structure and cholesterol of phytosterol are closely similar.The area of they and cholesterol It is not only that C24 additional methyl groups (campesterol) or ethyl (sitosterol), or in C22 other double bond (difference For brassicasterol, stigmasterol).But this small architectural difference leads to the metabolism of phytosterol and cholesterol in mammal Destiny is very different.Cholesterol and phytosterol all pass through Niemann-PickC1-Like1NPC1L1) transport protein glued by intestines Theca cell internalization.Cholesterol is transported to endoplasmic reticulum, it passes through acyl-CoA there: cholesterol O-acyl transferase 2 (Acat2) effect is sterilized, for mixing chylomicron.
In recent years, the research of phytosterol and its derivative causes of the invention since it reduces the effect of cholesterol Note that also interested in the potential association between circulation phytosterol and CVD risk.Phytosterol can undergo oxidation and be formed Xyphytolsols, this is proved to be the potential medium of CVD risk, because it shows about 1.4% in phytosterol patients serum Circulation sitosterol with its oxidised form presence.However, phytosterol is poor Acat2 substrate, therefore pass through heterodimer ATP combination box (Abc) half transport protein g5 and g8 are transported back chamber film to be secreted into enteric cavity again.Abcg5 and Abcg8 are present in The teleblem of enterocyte, is also expressed in liver.Discovery phytosterol may participate in anti-oxidant, cancer recently, and maintain just Normal nervous function and other effects.But the combination of few paper concern phytosterols and metabolic syndrome.
According to known to the present invention, this report shows the correlation of phytosterol with metabolic syndrome for the first time.As it appears from the above, plant Sterol levels and blood pressure, BMI, fasting blood-glucose, total cholesterol, triglycerides, LDL cholesterol level and hs-CRP are negatively correlated (equal P < 0.01).Phytosterol and waistline be negatively correlated and waist-to-hipratio (P < 0.01), but with the age, smoking drinks, HbA1c without Correlation.In addition, phytosterol and serum High Density Lipoprotein Cholesterol are positively correlated (r=0.15, P=0.03).
In result of study of the invention, this report shows that phytosterol has accumulated all indexs, such as BMI, TC, TG for the first time With the blood pressure of metabolic syndrome.It has also been found that the consumption figure of high sugar patient is lower than the normal consumption of metabolic syndrome patient, This may be related with strict control of diet, reduces food, especially oily, preferred treatment method of the nut as diabetes.This hair Bright experiment is also clear that confirmation high-density lipoprotein cholesterol and phytosterol are positively correlated with intake phytosterol.Other grind Study carefully confirmation, the intake of phytosterol can reduce low density lipoprotein cholesterol (LDL-C) concentration.Phytosterol and metabolic syndrome There are negatively correlated, blood pressure unrelated with the age, diabetes, BMI, WC, HbA1c, FBG, TG, TC, LDL-C, HDL-C and hs- CRP is included as independent variable.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.

Claims (4)

1.一种治疗代谢综合征发病药物，其特征在于，所述治疗代谢综合征发病药物为物甾醇。1. A drug for treating the onset of metabolic syndrome, characterized in that, the drug for treating the onset of metabolic syndrome is a phytosterol. 2.一种如权利要求1所述治疗代谢综合征发病药物的测定方法，其特征在于，所述治疗代谢综合征发病药物的测定方法包括以下步骤：2. an assay method for treating metabolic syndrome onset medicine as claimed in claim 1, is characterized in that, the assay method of described treatment metabolic syndrome onset medicine comprises the following steps: 步骤一，进行卡方检验或t检验以比较研究样本在MetS状态方面的特征；使用MetS重复分析；Step 1, conduct chi-square test or t-test to compare the characteristics of research samples in terms of MetS status; use MetS to repeat the analysis; 步骤二，计算皮尔森相关系数以评估摄入植物甾醇与临床和实验室测量之间的关联；使用多重逻辑回归分析来计算代谢综合征的存在的调整的奇数比OR，并且分析的结果以OR表示，具有95％置信区间CI；In step two, Pearson correlation coefficients were calculated to assess the association between intake of phytosterols and clinical and laboratory measures; multiple logistic regression analysis was used to calculate the adjusted odd ratio OR for the presence of metabolic syndrome, and the results of the analysis were expressed as OR It means that 95 % confident interval CI; 步骤三，统计分析均使用SPSS19.0版进行P值<0.05被认为是显著的。In step 3, statistical analysis was performed using SPSS version 19.0. P values <0.05 were considered significant. 3.如权利要求2所述的治疗代谢综合征发病药物的测定方法，其特征在于，所述治疗代谢综合征发病药物的测定方法诊断代谢综合征的标准：(1)腹部肥胖，腰围：男性>90cm，女性>85cm或BMI>30Kg/m2；(2)空腹甘油三酯增加>1.7mmol/L或150mg/dl；(3)LDL-C增加：男性<0.9mmol/L，<35mg/dl，女性<1.0mmol/L，<1.0mg/d1；(4)血压升高>140/90mmHg或治疗抗高血压；(5)空腹血糖水平高；或葡萄糖耐量降低或胰岛素抵抗或糖尿病；(6)尿白蛋白与肌酸酐的比例：>30mg/g或白蛋白排泄率20g/min。3. the assay method of the medicine for treating the onset of metabolic syndrome as claimed in claim 2, characterized in that, the assay method of the medicine for treating the onset of metabolic syndrome diagnoses the standard of metabolic syndrome: (1) abdominal obesity, waist circumference: male >90cm, female >85cm or BMI>30Kg/m2; (2) fasting triglyceride increase >1.7mmol/L or 150mg/dl; (3) LDL-C increase: male <0.9mmol/L, <35mg/dl , female <1.0mmol/L, <1.0mg/d1; (4) elevated blood pressure >140/90mmHg or antihypertensive treatment; (5) high fasting blood glucose level; or impaired glucose tolerance or insulin resistance or diabetes; (6) ) Ratio of urinary albumin to creatinine: >30mg/g or albumin excretion rate 20g/min. 4.如权利要求2所述的治疗代谢综合征发病药物的测定方法，其特征在于，所述治疗代谢综合征发病药物的测定方法的T2DM或IFG由以下所有的定义确定：(1)空腹血糖水平<100mg/dl；(2)口服降糖药或胰岛素治疗；(3)报告糖尿病史。4. the assay method for the treatment of metabolic syndrome onset medicine as claimed in claim 2, is characterized in that, T2DM or IFG of the assay method of described treatment metabolic syndrome onset medicine is determined by following all definitions: (1) fasting blood glucose Level <100mg/dl; (2) oral hypoglycemic agents or insulin therapy; (3) report history of diabetes.
CN201811548146.4A 2018-12-18 2018-12-18 It is a kind of to treat metabolic syndrome morbidity drug and its measuring method Pending CN109513006A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811548146.4A CN109513006A (en) 2018-12-18 2018-12-18 It is a kind of to treat metabolic syndrome morbidity drug and its measuring method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811548146.4A CN109513006A (en) 2018-12-18 2018-12-18 It is a kind of to treat metabolic syndrome morbidity drug and its measuring method

Publications (1)

Publication Number Publication Date
CN109513006A true CN109513006A (en) 2019-03-26

Family

ID=65796264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811548146.4A Pending CN109513006A (en) 2018-12-18 2018-12-18 It is a kind of to treat metabolic syndrome morbidity drug and its measuring method

Country Status (1)

Country Link
CN (1) CN109513006A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112067600A (en) * 2020-09-14 2020-12-11 中国水利水电科学研究院 A method for determining stable fingerprint recognition factors
WO2024046160A1 (en) * 2022-09-02 2024-03-07 广东药科大学 System for comprehensively evaluating glycolipid metabolic level and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105770A1 (en) * 2003-05-31 2004-12-09 Forbes Medi-Tech Inc. Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
CN101039585A (en) * 2004-08-10 2007-09-19 酶学技术有限公司 Mixture of phytosterol ester(s) and 1,3-diglyceride(s) for use in the treatment of medical conditions
US20130224317A1 (en) * 2010-10-26 2013-08-29 Fhg Corporation D/B/A Integrity Nutraceuticals Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
CN104379214A (en) * 2012-07-23 2015-02-25 雀巢产品技术援助有限公司 Kudzu and phytosterols for use in the treatment of metabolic disorders
CN104411319A (en) * 2012-07-23 2015-03-11 雀巢产品技术援助有限公司 Hawthorn and phytosterols and their effect on metabolic disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105770A1 (en) * 2003-05-31 2004-12-09 Forbes Medi-Tech Inc. Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes
CN101039585A (en) * 2004-08-10 2007-09-19 酶学技术有限公司 Mixture of phytosterol ester(s) and 1,3-diglyceride(s) for use in the treatment of medical conditions
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
US20130224317A1 (en) * 2010-10-26 2013-08-29 Fhg Corporation D/B/A Integrity Nutraceuticals Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
CN104379214A (en) * 2012-07-23 2015-02-25 雀巢产品技术援助有限公司 Kudzu and phytosterols for use in the treatment of metabolic disorders
CN104411319A (en) * 2012-07-23 2015-03-11 雀巢产品技术援助有限公司 Hawthorn and phytosterols and their effect on metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
梁润平等: "全谷物对代谢综合征调控效应的研究进展" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112067600A (en) * 2020-09-14 2020-12-11 中国水利水电科学研究院 A method for determining stable fingerprint recognition factors
CN112067600B (en) * 2020-09-14 2021-06-29 中国水利水电科学研究院 A method for determining stable fingerprint recognition factors
WO2024046160A1 (en) * 2022-09-02 2024-03-07 广东药科大学 System for comprehensively evaluating glycolipid metabolic level and use thereof

Similar Documents

Publication Publication Date Title
Grundy Pre-diabetes, metabolic syndrome, and cardiovascular risk
Hu et al. Tianjin Gestational Diabetes Mellitus Prevention Program: study design, methods, and 1-year interim report on the feasibility of lifestyle intervention program
Kirwan et al. A whole-grain diet reduces cardiovascular risk factors in overweight and obese adults: a randomized controlled trial
Beulens et al. High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study
Rondanelli et al. Appetite control and glycaemia reduction in overweight subjects treated with a combination of two highly standardized extracts from Phaseolus vulgaris and Cynara scolymus
Dove et al. Lupin and soya reduce glycaemia acutely in type 2 diabetes
Revilla et al. Hypoglycemic effect of Equisetum myriochaetum aerial parts on type 2 diabetic patients
Vrolix et al. Effects of glycemic load on metabolic risk markers in subjects at increased risk of developing metabolic syndrome
Gilardini et al. Effect of a modest weight loss in normalizing blood pressure in obese subjects on antihypertensive drugs
Nobarani et al. Visceral adipose tissue and non-alcoholic fatty liver disease in patients with type 2 diabetes
Rajaie et al. Moderate replacement of carbohydrates by dietary fats affects features of metabolic syndrome: a randomized crossover clinical trial
Pandurevic et al. Efficacy of very low-calorie ketogenic diet with the Pronokal® method in obese women with polycystic ovary syndrome: a 16-week randomized controlled trial
Amin et al. Clinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients
Bochar et al. Metabolic syndrome, overweight, hyperleptinemia in children and adults
Anusha et al. Lipid-lowering effects of foxtail millet (Setariaitalica) and quinoa (Chenopodium quinoawild) in pre-diabetics
CN109513006A (en) It is a kind of to treat metabolic syndrome morbidity drug and its measuring method
Shahid et al. Association of hyperuricemia with metabolic syndrome and its components in an adult population of Faisalabad, Pakistan
Osonoi et al. Effects of barley intake on glycemic control in Japanese patients with type 2 diabetes mellitus undergoing antidiabetic therapy: a prospective study
Goff et al. Carbohydrate-induced manipulation of insulin sensitivity independently of intramyocellular lipids
CN109596844A (en) It is a kind of to detect the drug and application that metabolic syndrome is fallen ill
Zalejska-Fiolka et al. Successful correction of hyperglycemia is critical for weight loss and a decrease in cardiovascular risk in obese patients
Hajishizari et al. The association between a low-carbohydrate diet score and the risk of diabetic nephropathy in women: A case-control study
Ramírez-Jiménez et al. Daily intake of a Phaseolus vulgaris L. snack bar attenuates hypertriglyceridemia and improves lipid metabolism-associated plasma proteins in Mexican women: A randomized clinical trial
Byrne et al. A study protocol for a randomised crossover study evaluating the effect of diets differing in carbohydrate quality on ileal content and appetite regulation in healthy humans
Geleva et al. A solubilized cellulose fiber decreases peak postprandial cholecystokinin concentrations after a liquid mixed meal in hypercholesterolemic men and women

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190326

RJ01 Rejection of invention patent application after publication